Zebrafish Prostate Cancer Models

Introduction Model Details Phenotypic Evaluation Applications Study Examples

Introduction

Prostate cancer is one of the most commonly diagnosed malignancies in men and a leading cause of cancer-related mortality worldwide. The disease arises from prostatic epithelial cells and is driven by androgen receptor (AR) signaling, with disease progression closely linked to genetic alterations in the AR pathway, PTEN loss, TMPRSS2-ERG fusions, and PI3K/AKT pathway activation. Early-stage disease may be asymptomatic or present with urinary symptoms, while advanced disease manifests with bone pain, pathologic fractures, and symptoms related to metastatic spread. Bone is the predominant site of prostate cancer metastasis, followed by lymph nodes, liver, and lung.

Current treatment for localized disease includes active surveillance, radical prostatectomy, and radiotherapy. Advanced and metastatic prostate cancer is managed with androgen deprivation therapy (ADT), AR signaling inhibitors such as enzalutamide and abiraterone, taxane-based chemotherapy, radioligand therapy, and PARP inhibitors in select patients. However, androgen-independent progression to castration-resistant prostate cancer (CRPC) and the emergence of neuroendocrine differentiation remain significant clinical challenges. Major research obstacles include AR pathway reactivation, metastasis to bone, lineage plasticity, and the lack of rapid in vivo models that capture the hormonal context of prostate cancer. Zebrafish prostate cancer models provide an efficient platform for evaluating tumor proliferation, AR pathway modulation, metastasis, and drug response in a vertebrate system.

Why Zebrafish?

Real-time Imaging: Transparent larvae enable real-time imaging of tumor cell dissemination and extravasation.
Rapid Assay: Short assay window supports rapid drug efficacy and toxicity assessment.
Hormonal Context: Hormonal supplementation allows modeling of AR pathway-dependent tumor behavior.
Translational Potential: Engraftment of patient-derived material supports translational research.

Available Zebrafish Disease Models

We offer a suite of prostate cancer models spanning AR-dependent growth, metastasis, and bone-homing phenotypes:

Model Name	Induction Method	Features
Prostate Cancer Cell Line Xenograft Model	Fluorescently labeled human prostate cancer cell lines, such as PC3, DU145, LNCaP, or 22Rv1, are transplanted into zebrafish embryos or larvae.	A practical model for evaluating tumor cell proliferation, survival, dissemination, and drug response. Suitable for rapid efficacy screening across AR-positive and AR-negative backgrounds.
Androgen-Responsive Prostate Cancer Xenograft Model	Androgen-sensitive prostate cancer cells are implanted into zebrafish larvae in the presence of exogenous testosterone, with or without AR-targeted agents.	Enables evaluation of AR pathway modulation, anti-androgen drug activity, androgen-dependent growth, and castration-resistant progression in a controlled in vivo setting.
Prostate Cancer Metastasis and Dissemination Model	Metastatic prostate cancer cell lines or patient-derived cells are transplanted into zebrafish embryos, and dissemination is tracked by fluorescence imaging.	Supports quantitative assessment of tumor cell migration, extravasation, and metastatic colonization. Suitable for anti-metastatic drug evaluation and mechanism studies.
Prostate Cancer Bone Metastasis Model	Prostate cancer cells with bone-metastatic tropism are implanted into zebrafish larvae, and dissemination to bone-associated regions is monitored.	A model for studying bone-homing behavior, tumor–bone microenvironment interaction, and compounds targeting metastatic prostate cancer to bone.

Phenotypic Evaluation

Drug Response and Safety

Reduction in tumor burden
Inhibition of dissemination or bone homing
Larval survival and gross morphology
Basic toxicity readouts, including edema and developmental delay

Metastasis and Dissemination

Number of disseminated tumor foci
Extravasation and migration distance
Bone-region colonization in metastasis models

AR Pathway and Tumor Biology

AR expression and downstream target modulation
Proliferation and apoptosis changes
EMT and stemness marker expression

Tumor Growth

Tumor fluorescence area or intensity
Tumor cell expansion over time
Tumor growth inhibition after treatment

Key Applications

In Vivo Drug Screening: In vivo prostate cancer drug screening for AR inhibitors, chemotherapies, and combination regimens.
AR Pathway Evaluation: Evaluation of anti-androgen agents and AR pathway modulators in androgen-responsive models.
Metastasis Studies: Metastasis and dissemination studies using live imaging of fluorescently labeled tumor cells.
Bone Metastasis Research: Bone metastasis research to assess tumor cell homing, colonization, and bone-targeted therapies.
Patient-Derived Profiling: Patient-derived tumor response profiling to support translational and personalized oncology research.

Study Examples

This study established a zebrafish prostate cancer xenograft model in the presence of exogenous testosterone. Androgen-sensitive prostate cancer cells were implanted into zebrafish larvae, and testosterone supplementation was shown to enhance tumor growth.

Fig. 1. Testosterone stimulates prostate cancer xenograft growth in zebrafish, and enzalutamide suppresses this androgen-dependent effect (Melong N, Steele S, et al. 2017).

The authors characterized the progression of human prostate cancer cells in a zebrafish xenograft model. Different prostate cancer cell lines were implanted into zebrafish embryos, and their growth, invasion, and dissemination were monitored by fluorescence imaging.

Fig. 2. Fluorescence imaging tracks prostate cancer cell dissemination and tumor progression in zebrafish xenografts over time (Xu W, Foster BA, et al. 2017).

Accelerate Prostate Cancer Research with Zebrafish Models

Advance prostate cancer research with zebrafish models for in vivo tumor growth analysis, AR pathway assessment, metastasis evaluation, and drug efficacy testing.

Contact Our Scientists

References

Melong N, Steele S, et al. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Scientific Reports 7, 14698 (2017).
Xu W, Foster BA, et al. Characterization of prostate cancer cell progression in zebrafish xenograft model. International Journal of Oncology 52(1), 252–260 (2018). doi:10.3892/ijo.2017.4189.

For research use only. Not intended for any clinical use.